dc.contributor.author
Lüftner, Diana
dc.contributor.author
Bauerfeind, Ingo
dc.contributor.author
Braun, Michael
dc.contributor.author
Brucker, Sara Y.
dc.contributor.author
Fasching, Peter A.
dc.contributor.author
Felberbaum, Ricardo
dc.contributor.author
Hagemann, Friederike
dc.contributor.author
Haidinger, Renate
dc.contributor.author
Harbeck, Nadia
dc.contributor.author
Hönig, Arnd
dc.contributor.author
Huober, Jens
dc.contributor.author
Jackisch, Christian
dc.contributor.author
Kolberg, Hans-Christian
dc.contributor.author
Kolberg-Liedtke, Cornelia
dc.contributor.author
Kühn, Thorsten
dc.contributor.author
Maass, Nicolai
dc.contributor.author
Reimer, Toralf
dc.contributor.author
Schneeweiss, Andreas
dc.contributor.author
Schumacher-Wulf, Eva
dc.contributor.author
Schütz, Florian
dc.contributor.author
Thomssen, Christoph
dc.contributor.author
Untch, Michael
dc.contributor.author
Wuerstlein, Rachel
dc.contributor.author
Thill, Marc
dc.date.accessioned
2020-10-19T14:48:00Z
dc.date.available
2020-10-19T14:48:00Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/28575
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-28324
dc.description.abstract
A German working group of leading breast cancer experts have discussed the votes at the International St. Gallen Consensus Conference in Vienna for the treatment of primary breast cancer with regard to the German AGO (Ar-beitsgemeinschaft Gynakologische Onkologie) recommendations for clinical practice in Germany. Three of the German breast cancer experts were also members of this year's St. Gallen panel. Comparing the St. Gallen recommendations with the annually updated treatment recommendations of the Gynecological Oncology Working Group (AGO Mamma 2019) and the German S3 Guideline is useful, because the recommendations of the St. Gallen panel are based on expert opinions of different countries and disciplines. The focus of this article is on systemic therapy. The motto of this year's 16th St. Gallen Consensus Conference was Estimating the magnitude of clinical benefit. The rationale behind this motto is that, for every treatment decision, a benefit-risk assessment must be taken into consideration for each patient.
en
dc.subject
St. Gallen Consensus Conference 2019
en
dc.subject
Early breast cancer
en
dc.subject
Locoregional therapy
en
dc.subject
Neoadjuvant treatment
en
dc.subject
Systemic therapy
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019)
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1159/000502603
dcterms.bibliographicCitation.journaltitle
Breast Care
dcterms.bibliographicCitation.number
5
dcterms.bibliographicCitation.originalpublishername
Karger
dcterms.bibliographicCitation.pagestart
315
dcterms.bibliographicCitation.pageend
324
dcterms.bibliographicCitation.volume
14
dcterms.rightsHolder.note
Copyright applies in this work.
dcterms.rightsHolder.url
http://rightsstatements.org/vocab/InC/1.0/
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.note.author
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
de
refubium.note.author
This publication is shared with permission of the rights owner and made freely accessible through a DFG (German Research Foundation) funded license at either an alliance or national level.
en
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
31798392
dcterms.isPartOf.issn
1661-3791
dcterms.isPartOf.eissn
1661-3805